Methods and compositions for treating polycystic ovary syndrome

1. A method of treating a subject suffering from polycystic ovary syndrome (PCOS), said method comprising administering to a subject suffering from PCOS an amount effective to treat at least one symptom of PCOS of a peptide compound capable of binding to and activating a GLP-1 receptor in vivo.

2. The method according to claim 1 , wherein the symptom is selected from the group consisting of insulin resistance, hyperinsulinemia, type-2 diabetes, obesity, hypertension, hyperlipidemia, anovulation or irregular ovulation, infertility, hyperandrogenism, hirsutism, alopecia, acne, enlarged multifollicular ovaries, abnormal uterine bleeding, and spontaneous abortion.

3. The method according to claim 1 , wherein the subject is a human.

4. The method according to claim 1 , wherein said peptide compound comprises a GLP-1 peptide or an exendin peptide.

5. The method according to claim 1 , wherein the peptide compound is administered by an infusion pump or by subcutaneous injection of a slow release formulation.

6. The method according to claim 1 wherein the peptide compound is administered with an agent selected from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose.

7. A method of reducing insulin resistance in a subject suffering from PCOS, said method comprising administering to a subject suffering from PCOS an amount effective to reduce insulin resistance, of a peptide compound capable of binding to and activating a GLP-1 receptor in vivo, wherein said insulin resistance is symptom of PCOS, to thereby reduce insulin resistance in said subject.

8. The method according to claim 7 , wherein the subject is a human.

9. The method according to claim 7 , wherein said peptide compound comprises a GLP-1 peptide or exendin peptide.

10. The method according to claim 7 , wherein the peptide compound is administered by an infusion pump or by subcutaneous injection of a slow release formulation.

11. The method according to claim 7 wherein the peptide compound is administered with an agent selected from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose.

12. A method of preventing the onset of type-2 diabetes in a subject suffering from PCOS, said method comprising administering to a subject suffering from PCOS an amount effective to prevent the onset of type-2 diabetes, of a peptide compound capable of binding to and activating a GLP-1 receptor in vivo, wherein said onset of diabetes is a symptom of PCOS, to thereby prevent the onset of type-2 diabetes in said subject.

13. The method according to claim 12 , wherein the subject is a human.

14. The method according to claim 12 , wherein said peptide compound comprises a GLP-1 peplide or an exendin peptide.

15. The method according to claim 12 , wherein the peptide compound is administered by an infusion pump or by subcutaneous injection of a slow release formulation.

16. The method according to claim 12 wherein the peptide compound is administered with an agent selected from the group consisting of an ovulation inducing drug, an anri-androgenic drug, an insulin-sensitizing agent and glucose.

17. A method of restoring regular menses in a subject suffering from PCOS, said method comprising administering to o subject suffering from PCOS an amount effective to restore regular menses, of a peptide compound capable of binding to and activating a GLP-1 receptor in vivo, wherein irregular menses is a symptom of PCOS, to thereby restore regular menses in said subject.

18. The method according to claim 17 , wherein the subject is a human.

19. The method according to claim 17 , wherein said peptide compound comprises a GLP-1 peptide or an exendin peptide.

20. The method according to claim 17 , wherein the peptide compound is administered by an infusion pump or by subcutaneous injection of a slow release formulation.

21. The method according to claim 17 wherein the peptide compound is administered with an agent seleced from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose.

22. A method of restoring regular ovulation in a subject suffering from PCOS, said method comprising administering to a subject suffering from PCOS an amount effective to restore reguIar ovulation, of a peptide compound capable of binding to and activating a GLP-1 receptor in vivo, wherein irregular ovulation is a symptom of PCOS, to thereby restore regular ovulation in said subject.

23. The method according to claim 22 , wherein the subject is a human.

24. The method according to claim 22 , wherein said peptide compound comprises a GLP-1 peptide or an exendin peptide.

25. The method according to claim 22 , wherein the peptide compound is administered by an infusion pump or by subcutaneous injection of a slow release formulation.

26. The method according to claim 22 wherein the peptide compound is administered with an agent selected from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose.

27. A method of restoring fertility in a subject suffering from PCOS, said method comprising administering to a subject suffering from PCOS an amount effective to restore fertility, of a peptide compound capable of binding to and activating a GLP-1 receptor in vivo, wherein reduced or absent fertility is a symptom of PCOS, to thereby restore fertility in said subject.

28. The method according to claim 27 , wherein the subject is a human.

29. The method according to claim 27 , wherein said peptide compound comprises a GLP-1 peptide or an exendin peptide.

30. The method according to claim 27 , wherein the peptide compound is administered by an infusion pump or by subcutaneous injection of a slow release formulation.

31. The method according to claim 27 wherein the peptide compound is administered with an agent selected from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose.

32. A method for preventing spontaneous abortion in a subject suffering from PCOS, said method comprising administering to a subject suffering from PCOS an amount effective to prevent spontaneous abortion, of a peptide compound capable of binding to and activating a GLP-1 receptor in vivo, wherein said spontaneous abortion is a symptom of PCOS, to thereby prevent spontaneous abortion in said subject.

33. The method according to claim 32 , wherein the subject is a human.

34. The method according to claim 32 , wherein said peptide compound comprises a GLP-1 peptide or an exendin peptide.

35. The method according to claim 32 , wherein the peptide compound is administered by an infusion pump or by subcutaneous injection of a slow release formulation.

36. The method according to claim 32 wherein the peptide compound is administered with an agent selected from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose.

37. The method of claim 1 , wherein said peptide compound comprises a GLP-1 peptide.

38. The method of claim 1 , wherein said peptide compound comprises exendin-3 or exendin-4.

39. The method of claim 38 , wherein said peptide compound comprises exendin-4 acid.

40. The method of claim 38 , wherein said peptide compound comprises exendin-4 amide.

41. The method of claim 1 , wherein said peptide compound comprises an exendin analog.

42. The method of claim 7 , wherein said peptide compound comprises a GLP-1 peptide.

43. The method of claim 7 , wherein said pepude compound comprises exendin-3 or exendin-4.

44. The method of claim 43 , wherein said peptide compound comprises exeridin-4 acid.

45. The method of claim 43 , wherein said peptide compound comprises exendin-4 amide.

46. The method of claim 7 , wherein said peptide compound comprises an exendin analog.

47. The method of claim 12 , wherein said peptide compound comprises a GLP-1 peptide.

48. The method of claim 12 , wherein said peptide compound comprises exendin-3 or exendin-4.

49. The method of claim 48 , wherein said peptide compound comprises exendin-4 acid.

50. The method of claim 48 , wherein said peptide compound comprises exendin-4 amide.

51. The method of claim 12 , wherein said peptide compound comprises an exendin analog.

52. The method of claim 17 , wherein said peptide compound comprises a GLP-1 peptide.

53. The method of claim 17 , wherein said peptide compound comprises exendin-3 or exendin-4.

54. The method of claim 53 , wherein said peptide compound comprises exendin-4 acid.

55. The method of claim 53 , wherein said peptide compound comprises exendin-4 amide.

56. The method of claim 17 , wherein said peptide compound comprises an exendin analog.

57. The method of claim 22 , wherein said peptide compound comprises a GLP-1 peptide.

58. The method of claim 22 , wherein said peptide compound comprises exendin-3 or exendin-4.

59. The method of claim 58 , wherein said peptide compound comprises exendin-4 acid.

60. The method of claim 58 , wherein said peptide compound comprises exendin-4 amide.

61. The method of claim 22 , wherein said peptide compound comprises an exendin analog.

62. The method of claim 27 , wherein said peptide compound comprises a GLP-1 peptide.

63. The method of claim 27 , wherein said peptide compound comprises exendin-3 or exendin-4.

64. The method of claim 63 , wherein said peptide compound comprises exendin-4 acid.

65. The method of claim 63 , wherein said peptide compound comprises exendin-4 amide.

66. The method of claim 27 , wherein said peptide compound comprises an exendin analog.

67. The method of claim 32 , wherein said peptide compound comprises a GLP-1 peptide.

68. The method of claim 32 , wherein said peptide compound comprises exendin-3 or exendin-4.

69. The method of claim 68 , wherein said peptide compound comprises exendin-4 acid.

70. The method of claim 68 , wherein said peptide compound comprises exendin-4 amide.

71. The method of claim 32 , wherein said peptide compound comprises an exendin analog.